Company: APXIF
Filing Date: 2025-01-22
Form Type: F-4
Source: 0001213900-25-005463
Chunk: 174

Company: APx Acquisition Corp. I
Filing Date: 2025-01-22
Form: F-4
Chunk 174
---
 Protection Act, or the Dodd -FrankAct, enacted in 2010, includes significant corporate governance and executive -compensation -relatedprovisions. Our management and other personnel need to devote a substantial amount of time to these compliance and disclosure obligations. If these requirements divert the attention of our management and personnel from other aspects of our business concerns, they could have a material adverse effect on our business, financial condition and results of operations. Moreover, these rules and regulations applicable to public companies substantially increase our legal, accounting and financial compliance costs, require that we hire additional personnel and make some activities more time consuming and costly. It may also be more expensive for us to obtain director and officer liability insurance. Our share price may be volatile and you could lose all or part of all of your investment. The trading price of our ordinary shares is volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. These factors include: •actual or anticipated fluctuations in our operating results; •effects of our strategic realignment and workforce reduction and our ability to achieve the intended benefits of these activities; •costs associated with our strategic realignment; •competition from existing tests or new tests that may emerge; •announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital commitments; •failure to meet or exceed financial estimates and projections of the investment community or that we provide to the public; 68 •issuance of new or updated research or reports by securities analysts or changed recommendations for our shares; •our substantial leverage and market perceptions regarding the same; •the level of short interest in our shares, and the effect of short sellers on the price of our shares; •actual or anticipated changes in regulatory oversight of our business; •additions or departures of key management or other personnel; •disputes or other developments related to our intellectual property or other proprietary rights, including litigation; •changes in reimbursement by current or potential payers; •general economic and market conditions; and •issuances of significant amounts of our ordinary shares. In addition, the stock market in general, and the market for shares of life sciences and technology companies in particular, has experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies. Broad market and industry factors, including the COVID -19pandemic, as well as general economic, political and geopolitical, and market conditions such as recessions, wars such as the current conflict in Palestine and